中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

750 records (took 0.072 seconds)

    QUINOLIZINONE TYPE COMPOUNDS
    41.
    发明申请
    QUINOLIZINONE TYPE COMPOUNDS 审中-公开
    喹诺酮类化合物

    公开(公告)号：WO1996039407A1

    公开(公告)日：1996-12-12

    申请号：PCT/US1996008991

    申请日：1996-06-05

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  CHU, Daniel, T. ,  LI, Qun ,  COOPER, Curt, S. ,  FUNG, Anthony, K., L. ,  LEE, Cheuk, M. ,  PLATTNER, Jacob, J. ,  MA, Zhenkun ,  WANG, Wei-Bo

    IPC: C07D471/04

    CPC classification number: C07D471/04 ,  A61K38/00 ,  C07D213/61 ,  C07D213/68 ,  C07D455/02 ,  C07K5/06026

    Abstract: Antibacterial compounds having formula (I) and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein A is =CR -; R is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R is selected from the group consisting of (a), (b), (c) and (d); R is halogen; R is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R is hydrogen, loweralkyl, halo(loweralkyl), or -NR R ; and R is halogen, loeralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

    Abstract translation: 具有式（I）的抗菌化合物及其药学上可接受的盐，酯和酰胺，其选择的优选实例包括其中A = CR 6 - 的那些化合物; R 1是3至8个碳原子的环烷基或取代的苯基; R 2选自（a），（b），（c）和（d）; R 3是卤素; R 4是氢，低级烷基，药学上可接受的阳离子或前药酯基; R 5是氢，低级烷基，卤代（低级烷基）或-NR 13 R 14; 和R 6是卤素，低级烷基，卤代（低级烷基），羟基取代的低级烷基，低级烷氧基（低级烷基），低级烷氧基或氨基（低级烷基），以及含有这些化合物的药物组合物及其在治疗中的用途 的细菌感染。

    WIDE DYNAMIC RANGE NUCLEIC ACID DETECTION USING AN AGGREGATE PRIMER SERIES
    43.
    发明申请
    WIDE DYNAMIC RANGE NUCLEIC ACID DETECTION USING AN AGGREGATE PRIMER SERIES 审中-公开
    使用聚合引物系列进行动态范围的核酸检测

    公开(公告)号：WO1996036736A2

    公开(公告)日：1996-11-21

    申请号：PCT/US1996007138

    申请日：1996-05-17

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  SOLOMON, Natalie, A. ,  BOUMA, Stanley, R.

    IPC: C12Q01/68

    CPC classification number: C12Q1/6851 ,  C12Q1/6834 ,  C12Q1/6862 ,  C12Q1/703 ,  C12Q1/706 ,  C12Q2537/143 ,  C12Q2527/143

    Abstract: The present invention provides a method of detecting the amount of a target sequence which may be present in a test sample. The method uses an aggregate primer series, which comprises at least two primer sets, in an amplification reaction to detect the relative concentration of a target sequence which may be present in a test sample. The primer sets have different sensitivities and hybridize with sub-target sequences which are different regions of the target sequence. The method generally comprises cycling a test sample suspected of containing a target sequence, an aggregate primer series, and means necessary for performing an amplification reaction; and detecting any amplified sub-target sequences. Based on a qualitative detection of the amplified sub-target sequences generated by individual primer sets, the relative quantity of the target sequence can be determined.

    Abstract translation: 本发明提供了检测可能存在于测试样品中的靶序列的量的方法。 该方法在扩增反应中使用包含至少两个引物组的聚集引物序列，以检测可能存在于测试样品中的靶序列的相对浓度。 引物组具有不同的灵敏度并与靶序列的不同区域的亚靶序列杂交。 该方法通常包括循环怀疑含有靶序列的测试样品，聚集引物序列和进行扩增反应所需的手段; 并检测任何扩增的亚靶序列。 基于由各引物组产生的扩增子靶序列的定性检测，可以确定目标序列的相对量。

    EMBEDDED EXPRESSION OF HETEROLOGOUS PROTEINS
    44.
    发明申请
    EMBEDDED EXPRESSION OF HETEROLOGOUS PROTEINS 审中-公开
    杂交蛋白的嵌入表达

    公开(公告)号：WO1996036722A2

    公开(公告)日：1996-11-21

    申请号：PCT/US1996006841

    申请日：1996-05-14

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  MAINE, Gregory, T. ,  CHOVAN, Linda, E.

    IPC: C12N15/72

    CPC classification number: C12N15/72 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  C12N2710/16122

    Abstract: A method for expressing a heterologous protein in a prokaryotic host cell, comprising the steps of: (a) providing a DNA vector having: (1) a control region operatively linked to a first genetic element encoding a carrier protein capable of expression in the host cell, and (2) a second genetic element encoding the heterologous protein, the second element being embedded within the first element such that the first and second elements are contiguous and in the same reading frame; (b) transforming the host cell with the DNA vector; and (c) expressing a fusion protein of the heterologous protein and the carrier protein, wherein the heterologous protein is joined at its N-terminus to a first domain of the carrier protein and at its C-terminus to a second domain of the carrier protein, and also a method for confirming intact expression of heterologous proteins, as well as fusion proteins, DNA constructs, plasmid vectors and transformed host cells relating to the above methods.

    Abstract translation: 一种用于在原核宿主细胞中表达异源蛋白质的方法，包括以下步骤：（a）提供DNA载体，所述DNA载体具有：（1）与编码能够在宿主中表达的载体蛋白的第一遗传元件可操作地连接的对照区 细胞，和（2）编码异源蛋白质的第二遗传元件，第二元素嵌入在第一元素内，使得第一和第二元素连续并且位于相同的阅读框中; （b）用DNA载体转化宿主细胞; 和（c）表达异源蛋白质和载体蛋白质的融合蛋白，其中所述异源蛋白质在其N末端连接至载体蛋白质的第一结构域，并且其C末端连接至载体蛋白质的第二结构域 ，以及用于确认异源蛋白质的完整表达以及与上述方法相关的融合蛋白，DNA构建体，质粒载体和转化的宿主细胞的方法。

    LIPOXYGENASE AND CYCLOOXYGENASE INHIBITING COMPOUNDS
    46.
    发明申请
    LIPOXYGENASE AND CYCLOOXYGENASE INHIBITING COMPOUNDS 审中-公开
    LIPOXYGENASE和CYCLOOXYGENASE抑制化合物

    公开(公告)号：WO1996032377A1

    公开(公告)日：1996-10-17

    申请号：PCT/US1996003907

    申请日：1996-03-22

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  BROOKS, Clint, D., W. ,  STEWART, Andrew, O. ,  BASHA, Anwer ,  BELL, Randy, L.

    IPC: C07C275/64

    CPC classification number: C07D409/12 ,  C07C275/64 ,  C07D307/52 ,  C07D333/20 ,  C07D333/58

    Abstract: Compounds having the structure of general formula (I) or a pharmaceutically acceptable salt thereof have activity as inhibitors of cyclooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optionally susbtituted carbocyclic aryl, (b) optionally substituted furyl, (c) optionally substituted benzo[b]furyl, (d) optionally substituted thienyl, (e) optionally substituted pyridyloxy, (f) optionally substituted pyridylalkyl, (g) optionally substituted benzo[b]thienyl, (h) optionally substituted pyridyl, (i) optionally substituted quinolyl, and (j) optionally substituted indolyl; X is selected from (a) optionally susbtituted alkyl, (b) optionally substituted alkenyl, and (c) optionally substituted alkynyl; R and R are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z-COOH.

    Abstract translation: 具有通式（I）结构的化合物或其药学上可接受的盐具有作为环加氧酶和5-脂氧合酶抑制剂的活性，降低了白三烯B4，C4，D4和E4以及环氧合酶产物如前列腺素和血栓素的生物合成， 可用于治疗炎症和过敏性疾病状态。 化合物具有上述结构，其中A选自（a）任选取代的碳环芳基，（b）任选取代的呋喃基，（c）任选取代的苯并[b]呋喃基，（d）任选取代的噻吩基，（e） 吡啶基氧基，（f）任选取代的吡啶基烷基，（g）任选取代的苯并[b]噻吩基，（h）任选取代的吡啶基，（i）任选取代的喹啉基，和（j）任选取代的吲哚基; X选自（a）任选的取代的烷基，（b）任选取代的烯基，和（c）任选取代的炔基; R 1和R 2独立地选自氢，羟基和烷基; Z为通式Z-COOH的非甾体抗炎药物的残基。

    INHIBITION OF C. DIFFICILE INFECTIONS BY INDIGESTIBLE OLIGOSACCHARIDES
    47.
    发明申请
    INHIBITION OF C. DIFFICILE INFECTIONS BY INDIGESTIBLE OLIGOSACCHARIDES 审中-公开
    C.可溶性低密度脂蛋白胆固醇感染的抑制作用

    公开(公告)号：WO1996031219A1

    公开(公告)日：1996-10-10

    申请号：PCT/US1996004665

    申请日：1996-04-04

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  WOLF, Brian, Warren ,  MEULBROEK, Jonathan, Allan ,  WHEELER, Keith, Brian ,  CAMPBELL, Shelia, Martinson ,  WALTON, Joseph, Edward

    IPC: A61K31/70

    CPC classification number: A61K31/7016 ,  A61K31/702 ,  A61K33/14 ,  A61K33/00 ,  A61K31/70 ,  A61K2300/00

    Abstract: The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection. An oral rehydration solution containing such indigestible oligosaccharides also provides fluid and electrolyte replacement.

    Abstract translation: 抗生素相关性腹泻（也称为假膜性结肠炎）的主要病因已经被认为是艰难梭菌。 据信，健康个体的土着微生物群落抑制了正常存在的艰难梭菌。 然而，当土着微生物群落被破坏时（例如，在抗生素治疗期间），可能发生艰难梭菌的过度生长，导致腹泻和结肠炎。 用抗生素治疗艰难梭菌已被证明是有效的，但多次发生复发; 而由于腹泻引起的脱水是一个加剧的问题。 有人认为微生物群落的正常化会抑制艰难梭菌的复发。 已经显示难消化的寡糖抑制艰难梭菌感染。 包含这种难消化的寡糖的口服补液溶液也提供流体和电解质替代物。

    A METHOD FOR EXPRESSING MODIFIED RECOMBINANT PROTEINS IN A BACTERIAL SYSTEM
    49.
    发明申请
    A METHOD FOR EXPRESSING MODIFIED RECOMBINANT PROTEINS IN A BACTERIAL SYSTEM 审中-公开
    一种在细菌体系中表达改性重组蛋白的方法

    公开(公告)号：WO1996027017A1

    公开(公告)日：1996-09-06

    申请号：PCT/US1996002623

    申请日：1996-02-27

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  MUKERJI, Pradip ,  THURMOND, M., Jennifer ,  HANSSON, L., Stig

    IPC: C12N15/64

    CPC classification number: C12N9/12 ,  A61K38/00 ,  C07K14/4732 ,  C07K2319/02 ,  C12N15/62 ,  C12N15/64 ,  C12N15/70

    Abstract: The present invention provides a method of producing a modified recombinant protein in a host cell using a single vector containing in tandem both the nucleotide sequence encoding an exogenous protein and an enzyme specific for modification of that protein. The invention also specifically provides a method of producing a recombinant phosphorylated human protein in a bacterial system using a single vector containing in tandem the nucleotide sequence encoding the human protein and a human kinase specific for phosphorylation of that protein.

    Abstract translation: 本发明提供了使用包含编码外源蛋白的核苷酸序列和对该蛋白质进行修饰的特异性酶的单一载体在宿主细胞中产生修饰的重组蛋白质的方法。 本发明还具体提供了在细菌系统中使用单一载体同时编码编码人蛋白质的核苷酸序列和对该蛋白质的磷酸化特异的人类激酶的生物质重组磷酸化人类蛋白质的方法。

    VOLUME VERIFICATION APPARATUS AND METHOD
    50.
    发明申请
    VOLUME VERIFICATION APPARATUS AND METHOD 审中-公开
    体积验证装置和方法

    公开(公告)号：WO1996024030A1

    公开(公告)日：1996-08-08

    申请号：PCT/US1996000611

    申请日：1996-01-17

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  VIEGUT, Todd, E. ,  KOTLARIK, John ,  WROBLEWSKI, Mieczyslaw ,  SLESZYNSKI, Neal, T. ,  FOWLER, John, Paul ,  SCHAPIRA, Thomas, Gerard ,  SMITH, Kenneth, Charles

    IPC: G01F23/284

    CPC classification number: G01N35/1016 ,  G01F23/266 ,  G01F23/268 ,  G01F23/284

    Abstract: Embodiments disclosed herein provide apparatus and methods for verifying a volume of fluid. According to one embodiment, an apparatus includes a receptacle for containing fluid, a first conductor operatively associated with the receptacle and a second conductor operatively associated with the receptacle offset from the first conductor. A source of a first electrical signal is electrically connected with the first conductor. A monitor is electrically connected with the second conductor for detecting a second electrical signal created in the second conductor. In another embodiment, a method includes positioning a receptacle adjacent a fluid dispense nozzle such that fluid dispensed from the nozzle enters the receptacle. A first electrical signal is applied to a first conductor operatively connected with the receptacle. A second electrical signal created in a second conductor operatively connected with the receptacle responsive to the first electrical signal is monitored.

    Abstract translation: 本文公开的实施例提供了用于验证流体体积的装置和方法。 根据一个实施例，一种装置包括用于容纳流体的容器，与所述容器可操作地相关联的第一导体和与所述容器可操作地相关联的与所述第一导体偏移的第二导体。 第一电信号的源与第一导体电连接。 监视器与第二导体电连接，用于检测在第二导体中产生的第二电信号。 在另一个实施例中，一种方法包括将容器定位在流体分配喷嘴附近，使得从喷嘴分配的流体进入容器。 第一电信号被施加到与插座可操作地连接的第一导体。 监视在响应于第一电信号与操作性地与插座连接的第二导体中产生的第二电信号。

Patent Agency Ranking